Effects of L-histidinol on the antitumour activity and acute cardiotoxicity of doxorubicin in mice

Pharmacological Research

Volumn 38, Issue 3, 1998, Pages 225-230

  Al Shabanah, Othman A ^a   Badary, Osama A ^a   Al Gharably, Naji M ^a   Al Sawaf, Hussein A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antitumour activity; Cardiotoxicity; Doxorubicin; L histidinol; Mice

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; HISTIDINOL; IMIDAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARDIOTOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; EHRLICH ASCITES TUMOR; FEMALE; LETHALITY; LIFESPAN; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032169285     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0355     Document Type: Article

References (35)

1. 1. Tan C, Etcubanas E, Wollner N, Rosen G, Gilladoga A, Showel J, Murphy ML, Krakoff IH. Adriamycin - An antitumor antibiotic in the treatment of neoplastic diseases. Cancer 1973; 32: 9-17.
2. 2. Frederickson P, Jorgenson S, Roesdahl K. Activity of adriamycin in metastatic breast cancer patients to a combination regimen of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone. Cancer 1974; 33: 519-26.
3. 3. Arcamone F. Properties of antitumor anthracyclines and new developments in their application. Cancer Res 1985; 45: 5995-9.
4. 4. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: A concise review. J Mol Cell Cardiol 1987; 19: 817-28.
5. 5. Rhoden W, Hasleton P, Brooks N. Anthracyclines and the heart. Br Hear J 1993; 70: 499-502.
6. 6. Doroshow JH, Lacker GY, Ifrim I, Myers CE. Prevention of doxorubicin cardiac toxicity in the mouse by Af-acetylcysteine. J Clin Invest 1981; 68: 1053-64.
7. 7. Tesoriere L, Ciaccio M, Valenza M, Bongiorno A, Maresi E. Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. J Pharmacol Exp Ther 1994; 269: 430-6.
8. 8. Singal PK, Siveski-Iliskovic N, Hill M, Thomas TP, Li T. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. Review. J Mol Cell Cardiol 1995; 27: 1055-63.
9. 9. Dorr RT. Cytoprotective agents for anthracyclines. Semin Oncol 1996; 23: 23-34.
10. 10. Al-Shabanah OA, Badary OA, Nagi MN, Al-Gharably NM, Al-Rikabi AM, Al-Bekairi AM. Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity. J Exp Clin Cancer Res 1998 (in press).
11. 11. Warrington RC, Muzyka TG, Fang WD. Histidinolmediated improvement in the specificity of 1-B-D-arabinofuranosylcytosine and 5-fluorouracil in L1210 leukemia-bearing mice. Cancer Res 1984; 44: 2929-35.
12. 12. Warrington RC, Fang WD. Histidinol-mediated enhancement of the specificity of two anticancer drugs in mice bearing leukemic bone marrow disease. J Natl Cancer Inst 1985; 74: 1071-7.
13. 13. Warrington RC. A novel approach for improving the efficacy of experimental cancer chemotherapy using combinations of anticancer drugs and L-histidinol. Anticancer Res 1986; 6: 451-64.
14. 14. Warrington RC, Cheng I, Fang WD. Effect of L-histidinol on the susceptibility of P815 mastocytoma cells to selected anticancer drugs in vitro and in BDA/2J mice. J Natl Cancer Inst 1987; 78: 1177-83.
15. 15. Warrington RC, Fang WD. L-Histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukemia. Br J Cancer 1989; 60: 652-6.
16. 16. Brandes LJ, Labella FS, Warrington RC. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists. J Natl Cancer Inst 1991; 83: 1329-36.
17. 17. Warrington RC. L-Histidinol in experimental cancer chemotherapy: improving the selectivity and efficacy of anticancer drugs, eliminating metastatic disease and reversing the multidrug-resistant phenotype. Biochem Cell Biol 1992; 70: 365-75.
18. 18. Badary OA, Moustafa AM, Abd El-Aziz AH, Hafez Y, Salama SA, Hamada FMA. The effects of co-administration of cisplatin and L-histidinol on cisplatin-induced antitumor activity and toxicity in mice bearing Ehrlich ascites carcinoma. J Egypt Soc Toxicol 1996; 16: 5-9.
19. 19. Badary OA, Nagi MN, Al-Sawaf HA, Al-Harbi MM, Al-Bekairi AM. Effect of L-histidinol on cisplatin nephrotoxicity in the rat. Nephron 1997; 77: 435-9.
20. 20. Geran RI, Greenberg NH, MacDonald M, Schumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 1972; 3: 1-103.
21. 21. Weisenthal L, Dill P, Kunick N, Lippman M. Comparison of dye exclusion assays with a cologenic assay in the determination of drug-induced cytotoxicity. Cancer Res 1983; 43: 258-84.
22. 22. Buhl SN, Jackson KY. Optimal conditions and comparisons of lactate dehydrogenase catalysis of the lactate to pyruvate and pyruvate to lactate reactions in human serum at 25, 30 and 37°C. Clin Chem 1978; 24: 828-31.
23. 23. Swanson JR, Wilkinson JH. Measurement of creatine kinase in serum. In: Cooper GR, ed. Standard methods of clinical chemistry. Vol 7, New York: Academic Press 33-42.
24. 24. Kachmar JF, Moss DW. Enzymes. In: Teitz W, ed. Fundamentals of clinical chemistry. Philadelphia, London, Mexico City: WB Saunders 1982; 565-95.
25. 25. Zaharko D, Plowman J, Waud W, Dykes D, Malspeies L. L-Histidinol: Preclinical studies in combination with antitumor agents and pharmacokinetic studies in mice. Cancer Res 1992; 52: 3604-9.
26. 26. Kohnoe S, Maehara Y, Takhashi I, Saito A, Okada Y, Sugimachi K. L-Histidinol potentiates hyperthermic cell killing in vitro. Int J Oncol 1993; 3/6: 835-40.
27. 3H]thymidine incorporation into DNA and the viability of cultured EAC cells. J Egypt Soc Toxicol 1995; 15: 81-6.
28. 28. Badary OA. L-Histidinol inhibition of the proliferation and DNA biosynthesis of Ehrlich ascites carcinoma. Bull Fac Pharm Cairo Univ 1995; 33: 73-7.
29. 29. Stolfi RL, Martin DS. Chemotherapeutic activity of L-histidinol against spontaneous, autochthonous murine breast tumors. Chemotherapy 1990; 36: 435-40.
30. 30. Ridgway HR, Stewart DP. L-histidinol improves the therapeutic efficacy of some conventional antitumor agents against the advanced B16 melanoma in mice. Proc Am Assoc Cancer Res 1988; 29: 480.
31. 31. Rosenoff SH, Oison HM, Young DM, Bostick F, Young RC. Adriamycin-induced cardiac damage in the mouse: a small-animal model of cardiotoxicity. J Natl Cancer Inst 1975; 55: 191-4.
32. 32. Kojima S, Takeshi I, Mayashi M, Kajiwara Y, Kitabatake K, Kubota K. Inhibitory effect of 5,6,7,8-tetrahydroneopterin on adriamycin-induced cardiotoxicity. J Pharmacol Exp Ther 1993; 266: 1699-704.
33. 33. Preus M, Bhargava AS, Khater AER, Gunzel P. Diagnostic value of serum creatine kinase and lactate dehydrogenase isozyme determination for monitoring early cardiac damage in rats. Toxicol Lett 1988; 42: 225-33.
34. 34. Sharkey SW, Murakami MM, Smith SA, Apple FS. Canine myocardial creatine kinase isozymes after chronic coronary artery occlusion. Circulation 1991; 84: 333-40.
35. 35. Luo X, Eurovsky Y, Cole D, Trines J, Benson LN, Lehotay DC. Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat. Biochim Biophys Acta 1997; 1360: 45-52.